Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines
- PMID: 6784299
Monoclonal antibody-recognizing tumor-associated antigen of DBA/2 mouse lymphoma L1210 and its sublines
Abstract
Tumor-associated antigens of DBA/2 lymphoma L1210 and three immunologic drug-resistant L1210 sublines were studied by monoclonal antibodies produced by fusing non-Ig secreting BALB/c myeloma cells with spleen cell of DBA/2 mice immunized with L1210 subline cells that are syngeneic with respect of DBA/2 mice. After the cell fusion, two stable clones of antibody-producing hybridomas were selected for further analysis of the antibody specificity by complement-dependent cytotoxicity and quantitative absorption tests. These clones produced a cytotoxic antibody(s) of IgG2 class recognizing a TAA(s) that was expressed strongly on cells of the immunizing subline as well as on cells of their L1210 sublines, but weakly on the parental L1210 cells. Control normal syngeneic mouse tissues and tumors of syngeneic and allogeneic origins, including those that carry known murine leukemia virus-associated antigens, showed no significant reaction with the antibody, whereas two DBA/2 tumors (i.e., L5178Y and p388-D1) showed weak reactivity. Since all three L1210 sublines were more immunogenic than the parental L1210 cells in eliciting host's tumor graft rejection and contained more TAA than the parent line, the data suggest that the monoclonal antibody obtained may be defining the TAA that is involved in tumor rejection.
Similar articles
-
Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.Cancer Res. 1983 Jun;43(6):2592-9. Cancer Res. 1983. PMID: 6342755
-
Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay.Cancer Res. 1975 Apr;35(4):946-52. Cancer Res. 1975. PMID: 1090366
-
Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline.Cancer Res. 1985 Nov;45(11 Pt 1):5299-303. Cancer Res. 1985. PMID: 4053006
-
[Mechanism of action and resistance of antineoplastic agents].Gan To Kagaku Ryoho. 1983 Nov;10(11):2245-51. Gan To Kagaku Ryoho. 1983. PMID: 6195971 Review. Japanese.
-
Monoclonal antibodies: technology and potential use.J Am Vet Med Assoc. 1982 Nov 15;181(10):1005-10. J Am Vet Med Assoc. 1982. PMID: 6757209 Review.
Cited by
-
Intratumor immunologic heterogeneity.Cancer Metastasis Rev. 1982;1(4):319-34. doi: 10.1007/BF00124215. Cancer Metastasis Rev. 1982. PMID: 6192904 Review.
-
Hybridomas: a new dimension in biological analyses.In Vitro. 1981 Dec;17(12):1036-50. doi: 10.1007/BF02618601. In Vitro. 1981. PMID: 6172364 Review.